FDA Approves First Gene Therapy for Aromatic L-amino Acid Decarboxylase (AADC) Deficiency: A Landmark in Rare Disease Treatment Read more about FDA Approves First Gene Therapy for Aromatic L-amino Acid Decarboxylase (AADC) Deficiency: A Landmark in Rare Disease Treatment By Vigilare Biopharma November 15, 2024FDA